# US 2014/0271588 A1 · Treatment of peripheral vascular disease using protein solutions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271588 A1
- Document ID: US20140271588A1
- Status: Published application
- Kind: A1
- Application number: 13/841,103
- Filed: 2013-03-15
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Biomet Biologics, LLC
- Applicants: Biomet Biologics, LLC
- Inventors: Matthew D. LANDRIGAN; Krista O'SHAUGHNESSEY; Jennifer E. WOODELL-MAY; David L. SUTER
- Web page: https://patentgrep.com/patent/US20140271588A1

## CPC

- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61K 35/19: Platelets; Megacaryocytes
- A61K 38/1703: {from vertebrates}
- A61K 38/1793: {for cytokines; for lymphokines; for interferons}
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating peripheral vascular disease comprising administering a protein solution site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII. The solution may also comprise white blood cells, platelets, concentrated bone marrow aspirate, and combinations thereof.

## Claims

### Claim 1

A method for treating peripheral vascular disease, comprising administering to the site of the disease a blood-derived composition comprising at least two proteins selected from the group consisting of IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII, wherein the concentration of each protein in the composition is greater than the concentration of the protein in normal blood.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the blood derived composition is autologous to the subject.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the blood derived composition comprises
a) at least about 10,000 pg/ml IL1-ra;
(b) at least about 1,200 pg/ml sTNF-RI; and
(c) a protein selected from the group consisting of sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII, and mixtures thereof, wherein the protein has a concentration higher than the protein's baseline concentration in normal blood.

### Claim 4

A method for treating peripheral vascular disease, comprising administering to the site of the disease a blood-derived composition comprising:
(a) interleukin-1 receptor antagonist (IL-1ra), at a concentration at least 3 times greater than the concentration of IL-1ra in normal blood;
(b) soluble tissue necrosis factor-r1 (sTNF-r1), at a concentration at least 2 times greater than the concentration of IL-1ra in normal blood;
(c) white blood cells at a concentration at least 2 times greater than the concentration of white blood cells in normal blood; and
(d) platelets, at a concentration at least 2 times greater than the concentration of platelets in normal blood.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the concentration of IL-1ra is from about 10,000 pg/ml to about 40,000 pg/ml, and the concentration of TNF-r1 from about 1,100 pg/ml to about 4,000 pg/ml.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the composition further comprises a protein selected from the group consisting of sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII, and mixtures thereof, wherein the concentration of the protein in the composition is greater than the concentration of the protein in normal blood.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the composition further comprises concentrated bone marrow aspirate.

### Claim 8

A method for treating peripheral vascular disease in a mammalian subject, comprising:
(a) obtaining a cytokine cell suspension from the subject;
(b) fractionating the liquid to produce an autologous protein solution comprising interleukin-1 receptor antagonist;
(c) administering the autologous protein solution to the site of the vascular disease in the subject.

### Claim 9 (depends on 8)

The method according to claim 8 wherein the cytokine cell suspension comprises whole blood, bone marrow aspirate, adipose tissue, urine, fractions thereof, and mixtures thereof.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the fractionating comprises placing blood in a container a separator operable to separate the blood into two or more fractions; and centrifuging the separator to create a platelet-rich plasma fraction.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the fractionating further comprises contacting the platelet-rich plasma with polyacrylamide beads, and separating the polyacrylamide beads from the platelet-rich plasma to form the autologous protein solution.

### Claim 12 (depends on 9)

The method according to claim 9, wherein the liquid is bone marrow aspirate.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the fractionating comprises:
(1) loading tissue comprising whole blood, bone marrow aspirate, or both, and an anticoagulant into a tube comprising a buoy disposed in the tube, wherein the buoy has a density such that the buoy reaches an equilibrium position upon centrifugation of the tissue in the tube, the equilibrium position being between a first fraction and a second fraction comprising cytokine-producing cells, the second fraction having a concentration of cytokine-producing cells greater than the concentration of cytokine-producing cells in the first fraction;
(2) centrifuging the tube so that the buoy defines an interface between the first fraction and the second fraction; and
(3) collecting the second fraction;
(4) loading the second fraction into a concentrator assembly comprising a solid extraction material and incubating the second fraction in contact with the solid extraction material; and
(5) rotating the concentrator assembly at centrifugal speeds to separate from the solid extraction material the solution rich in interleukin-1 receptor antagonist having a concentration of interleukin-1 receptor antagonist greater than that of the whole blood.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the solid extraction material is selected from the group consisting of corundum, quartz, titanium, dextran, agarose, polyacrylamide, polystyrene, polyethylene, polyvinyl chloride, polypropylene, and combinations thereof.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the solid extraction material comprises polyacrylamide.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the solid extraction material comprises a form selected from the group consisting of a bead, fiber, powder, porous material, and combinations thereof.

### Claim 17 (depends on 8)

The method according to claim 8, further comprising:
(d) obtaining bone marrow aspirate from the subject;
(e) concentrating the bone marrow aspirate to produce a concentrated bone marrow aspirate (cBMA);
(f) administering the cBMA to the subject.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the administering of the cBMA is performed concurrently with the administering of the autologous protein solution.

### Claim 19 (depends on 8)

The method according to claim 8, wherein the mammalian subject is human.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the mammalian subject is a companion, working, or sports animal.

### Claim 21 (depends on 8)

The method according to claim 8, wherein the cytokine cell suspension is autologous to the mammalian subject.

### Claim 22 (depends on 8)

The method according to claim 8, further comprising administering to the site of the disease a composition comprising mesenchymal stem cells.

### Claim 23 (depends on 22)

The method according to claim 22, comprising administering to the site concentrated bone marrow comprising the mesenchymal stem cells.

### Claim 24 (depends on 8)

The method according to claim 8, wherein the liquid comprises bone marrow aspirate.

### Claim 25 (depends on 8)

The method according to claim 8, wherein administering the composition is performed by an intramuscular injection at a site of the peripheral vascular disease.
